| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d667d655d078f7fd940f008043ccc62 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2400-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L71-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3834
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L5-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L71-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L5-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-52 |
| filingDate |
2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce370290641145bda05d3f076b75826a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b45611409b2023440d28f3eb98c3ff2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70efc4901f6aea6236e9d46065dc865c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98af1242bf3bb1c1452529701ba71fde |
| publicationDate |
2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018280446-A1 |
| titleOfInvention |
Agent for Treating Urinary Incontinence Including Stem Cells Derived from Amniotic Fluid |
| abstract |
The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions. That is, the stem cells derived from amniotic fluid of the present invention are differentiated into muscles in-situ, and the differentiation into muscles can thus be achieved only with cells in order to recover muscle functions. |
| priorityDate |
2011-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |